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Status epilepticusLacosamide is a new antiepileptic drug that has been successfully used for the treatment of partial seizures.
We report three neurosurgical cases of simple partial status epilepticus refractory to multiple antiepileptic
medications. The addition of oral lacosamide in doses of 200–400 mg in combinationwith the existing treatment
had successfully controlled the seizures within four days.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Simple partial status epilepticus (SPSE) is characterized by partial
seizures, without impairment of consciousness or secondary general-
ization and preservation of neurovegetative regulation.
Lacosamide is a new antiepileptic drug, licensed in the USA and
Europe, for adjunctive therapy of partial onset seizures in 2008. In
this article, we present three patients with refractory SPSE, which
was successfully controlled with the addition of oral lacosamide in
their treatment.2. Case presentation
2.1. 1st case
A 52-year-old female underwent a craniotomy in our department
for a metastatic tumor in the left parietal lobe. The patient had no
complications and was discharged on the 7th postoperative day,
under levetiracetam on a dosage of 1500 mg bid and phenytoin on
a dosage of 100 mg tid. Two months later, she presented again with
focal seizures in her right arm. The blood levels of phenytoin werethens, Greece.
eorgiou).
nc.Open access under CC BY-NC-ND lislightly over 20 μg/ml. The electroencephalogram (EEG) showed
spikes and δ waves. Oral lacosamide was added starting with an ini-
tial dosage of 100 mg bid and four days after, it was increased to
200 mg bid. On the fourth day after the addition of oral lacosamide,
seizures were totally controlled, and phenytoin treatment was
interrupted. The patient was discharged home seizure-free ten days
after the initiation of lacosamide.
2.2. 2nd case
A 66-year-old male underwent a craniotomy in our department
for an acute subdural hematoma after a head trauma. Postoperatively,
he remained in the intensive care unit for one month.
Three days after his transfer to theward, he presentedwithmyoclonic
jerks of his right arm. He was already under phenytoin on a dosage
of 150 mg tid. We added levetiracetam with a starting dosage of
1000 mg bid, without complete control of the status. We increased
levetiracetam up to 1500 mg bid, but the seizures were refractory to
the treatment. We ﬁnally added 100 mg bid of oral lacosamide. After
gradual increase of the dosage at 200 mg bid, the seizures were totally
controlled three days after, and the patient was discharged seizure-free.
2.3. 3rd case
An 80-year-old female was admitted to our department because of
a small right acute subdural hematoma, with no midline shift, after a
head injury. Her neurological examination revealed mild left-sided
postictal weakness. We decided to treat her conservatively. Phenytoincense.
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the patient presented focal motor seizures in her left hand. Although
we added 500 mg bid of levetiracetam to her treatment, she contin-
ued to have seizures. On the second day, we started 100 mg bid of
oral lacosamide and three days after, the seizures were completely
controlled. The patient was discharged home seizure-free twelve
days after her injury.3. Discussion
Administration of antiepileptic drugs (AEDs) is the mainstay of
treatment for SPSE. Although almost 50% of patients become
seizure-free with the ﬁrst AED regardless of the agent, a substantial
proportion of patients still have inadequate seizure control despite
treatment with currently available AEDs [1].
Lacosamide has been approved for add-on treatment of partial sei-
zures with or without secondary generalization in patients 16 years of
age or older at a daily dose of 200 mg to 400 mg. Lacosamide has
a novel dual mechanism of action. The active substance is (R)-2-
acetamido-N-benzyl-3-methoxyproionamide. It selectively enhances
slow inactivation of voltage-gated sodium channels, resulting in stabili-
zation of hyperexcitable neuronal membranes and inhibition of repeti-
tive neuronalﬁringwithout exhibiting effects on physiological neuronal
excitability [2].
Being a newly introduced pharmacologic agent until now, there are
only a handful of case reports and series in the literature demonstrating
the beneﬁts of lacosamide as an adjuvant therapy. Kellinghaus et al. ana-
lyzed 39 patients, whowere admitted for status epilepticus, with amean
age of 63 years old. Out of the abovementioned patients, 16 presented
SPSE. All but two patients previously received benzodiazepines, and
lacosamide was started, in an initial dose between 200 and 400 mg,
after a median latency of 30 h. Lacosamide successfully terminated the
seizures in 44% of the patients [2]. Rantsch et al. concluded that adminis-
tering lacosamide, as a fourth drug, in doses of 50–100 mg daily, effec-
tively terminated SPSE in 20% of the cases. However, they supported
the observation that the outcome at discharge seemed to depend consid-
erably on the age of the patient and not on the therapeutic approach [3].Chen et al. presented a case of a 57-year-old male with refractory SPSE,
already under levetiracetam,who became seizure-free after the initiation
of lacosamide at an initial dosage of 50 mg bid and then gradually
increased to 200 mg bid [4].
Our series includes three patients, with a mean age of 66 years old,
who suffered from SPSE because of a space-occupying lesion. Our expe-
rience demonstrates that oral lacosamide, in doses of 200–400 mg
daily, can successfully control partial motor status, as an adjuvant to
the already established antiepileptic treatment. In all cases, SPSE was
totally controlled within four days, and no adverse effects were noted.
4. Conclusion
Oral lacosamide is a useful antiepileptic drug for refractory SPSE. Its
mechanism of action might indicate that the drug could be advanta-
geous in combination therapy. However, further reports are necessary
to determine optimal timing, dosing, and duration of lacosamide treat-
ment as well as its effectiveness as a ﬁrst choice antiepileptic drug.
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